{"database": "lobbying", "table": "lobbying_filings_raw", "rows": [["78b4ccbc-ffb5-4c8d-a8ed-ebe16ed3b5a2", "Q1", 400918672, "PENN AVENUE PARTNERS", 196187, "PURDUE PHARMA L.P.", 2018, "first_quarter", "2018-04-18T14:32:05.810000-04:00", 60000.0, 0, 0, 0, "{\"url\": \"https://lda.senate.gov/api/v1/filings/78b4ccbc-ffb5-4c8d-a8ed-ebe16ed3b5a2/\", \"filing_uuid\": \"78b4ccbc-ffb5-4c8d-a8ed-ebe16ed3b5a2\", \"filing_type\": \"Q1\", \"filing_type_display\": \"1st Quarter - Report\", \"filing_year\": 2018, \"filing_period\": \"first_quarter\", \"filing_period_display\": \"1st Quarter (Jan 1 - Mar 31)\", \"filing_document_url\": \"https://lda.senate.gov/filings/public/filing/78b4ccbc-ffb5-4c8d-a8ed-ebe16ed3b5a2/print/\", \"filing_document_content_type\": \"text/html\", \"income\": \"60000.00\", \"expenses\": null, \"expenses_method\": null, \"expenses_method_display\": null, \"posted_by_name\": \"Timothy F. Hannegan\", \"dt_posted\": \"2018-04-18T14:32:05.810000-04:00\", \"termination_date\": null, \"registrant_country\": \"United States of America\", \"registrant_ppb_country\": null, \"registrant_address_1\": \"101 Constitution Avenue, NW\", \"registrant_address_2\": \"Suite L110\", \"registrant_different_address\": false, \"registrant_city\": \"Washington\", \"registrant_state\": \"DC\", \"registrant_zip\": \"20001\", \"registrant\": {\"id\": 400918672, \"url\": \"https://lda.senate.gov/api/v1/registrants/400918672/\", \"house_registrant_id\": 42026, \"name\": \"PENN AVENUE PARTNERS\", \"description\": \"â\\u20ac\\u2039Government Affairs.\", \"address_1\": \"701 Pennsylvania Avenue, NW\", \"address_2\": \"Suite 230\", \"address_3\": null, \"address_4\": null, \"city\": \"Washington\", \"state\": \"DC\", \"state_display\": \"District of Columbia\", \"zip\": \"20004\", \"country\": \"US\", \"country_display\": \"United States of America\", \"ppb_country\": \"US\", \"ppb_country_display\": \"United States of America\", \"contact_name\": \"BETH ANNE COLE\", \"contact_telephone\": \"+1 202-256-5643\", \"dt_updated\": \"2026-01-27T13:57:41.474980-05:00\"}, \"client\": {\"id\": 196187, \"url\": \"https://lda.senate.gov/api/v1/clients/196187/\", \"client_id\": 505, \"name\": \"PURDUE PHARMA L.P.\", \"general_description\": \"Pharmaceutical company.\", \"client_government_entity\": false, \"client_self_select\": null, \"state\": \"DC\", \"state_display\": \"District of Columbia\", \"country\": \"US\", \"country_display\": \"United States of America\", \"ppb_state\": \"CT\", \"ppb_state_display\": \"Connecticut\", \"ppb_country\": \"US\", \"ppb_country_display\": \"United States of America\", \"effective_date\": \"2017-04-07\"}, \"lobbying_activities\": [{\"general_issue_code\": \"PHA\", \"general_issue_code_display\": \"Pharmacy\", \"description\": \"Monitoring legislative and regulatory activities impacting the pharmaceutical industry.\", \"foreign_entity_issues\": \"\", \"lobbyists\": [{\"lobbyist\": {\"id\": 56689, \"prefix\": \"mr\", \"prefix_display\": \"MR.\", \"first_name\": \"TIMOTHY\", \"nickname\": null, \"middle_name\": \"FARRELL\", \"last_name\": \"HANNEGAN\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": \"U.S. General Accounting Office\", \"new\": false}], \"government_entities\": [{\"id\": 1, \"name\": \"SENATE\"}]}], \"conviction_disclosures\": [], \"foreign_entities\": [], \"affiliated_organizations\": []}"]], "columns": ["filing_uuid", "filing_type", "registrant_id", "registrant_name", "client_id", "client_name", "filing_year", "filing_period", "received_date", "amount_reported", "is_amendment", "is_no_activity", "is_termination", "raw_json"], "primary_keys": ["filing_uuid"], "primary_key_values": ["78b4ccbc-ffb5-4c8d-a8ed-ebe16ed3b5a2"], "units": {}, "query_ms": 4.930512979626656, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}